The activation of the biguanide antimalarial proguanil co‐segregates with the mephenytoin oxidation polymorphism‐a panel study.

British Journal of Clinical Pharmacology

Volumn 31, Issue 6, 1991, Pages 689-692

  Ward, SA ^a   Helsby, NA ^a   Skjelbo, E ^a   Brosen, K ^a   Gram, LF ^a   Breckenridge, AM ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOGUANIL; CYTOCHROME P450; MEPHENYTOIN; PROGUANIL; SPARTEINE; SPARTEINE SULFATE;

ADULT; ARTICLE; DRUG OXIDATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC ACTIVATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; CHLOROGUANIDE; FEMALE; HUMAN; MALE; MEPHENYTOIN; OXIDATION-REDUCTION; PHENOTYPE; POLYMORPHISM (GENETICS); REFERENCE VALUES; SPARTEINE; SUPPORT, NON-U.S. GOV'T; TRIAZINES;

EID: 0025735576     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1991.tb05594.x     Document Type: Article

References (27)

1. Interactions between nutritional factors and drugbiotransformationinman
2. Metabolism of chlorguanide a unique mixed function oxidase substrate
3. Cyclisation and N‐dealkylation of chlorguanide by rabbit and rat hepatic microsomes
4. Sparteine oxidation polymorphism in Denmark
5. Clinical significance of the sparteine/debrisoquine oxidation polymorphism (Special Article)
6. A metabolite of paludrine with high antimalarial activity
7. Contribution of environmental factors to variability in human drug metabolism
8. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark
9. Defective N‐oxidation of sparteine in man: a new pharmacogenetic defect
10. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism
11. In vitro metabolism of the biguanide antimalarials in human liver microsomes: eividence for a role of the mephenytoin hydroxylase (P450mp) enzyme
12. Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians
13. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man
14. Polymorphic hydroxylation of debrisoquine in man
15. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations
16. The P450 superfamily: Update on listing of all genes recommended nomenclature of the chromosomal loci
17. S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after co‐administration with debrisoquine
18. The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine
19. Determination of proguanil and its metabolites cycloguanil and 4‐chlorphenylbiguanide in plasma, whole blood and urine by h.p.l.c
20. Genetic and environmental factors affecting drug disposition in man
21. Sparteine metabolism in Canadian Caucasians
22. S‐mephenytoin 4‐hydroxylase is inherited as an autosomal‐recessive trait in Japanese families
23. Inter‐subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man
24. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil
25. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism
26. Genetic polymorphism of S‐mephenytoin hydroxylation